Brain-signaling peptide that probes appetite and sexual-function pathways (gamma2-MSH-Arg)
A natural hormone fragment that weakly activates a brain receptor involved in appetite and sexual function; used only as a lab research tool.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
γ2-MSH-Arg is a 13-residue fragment of the hormone precursor proopiomelanocortin (POMC). POMC is the master peptide precursor that the body processes into several hormones — including the stress hormone ACTH and the pigmentation-related α-MSH — and γ2-MSH is one of several smaller melanocyte-stimulating hormone fragments released from its N-terminal region. The "-Arg" in the name refers to a C-terminal arginine residue retained at the dibasic cleavage site after prohormone convertase processing, making this a 13-amino-acid form (YVMGHFRWDRFGR) rather than the canonical 12-residue γ2-MSH (YVMGHFRWDRFG). It is used primarily as a pharmacological probe to study the melanocortin receptor family, particularly MC3R and MC4R.
History
The γ-MSH sequence was identified in 1979–1980 following the cloning of the POMC gene, which revealed a previously unknown MSH-like region in POMC's N-terminal domain. Benjannet, Seidah, Routhier, and Chrétien (Nature, 1980) isolated and characterized a novel human pituitary peptide containing this γ-MSH sequence, confirming that human and bovine γ-MSH share identical amino acid composition. Subsequent chromatographic work by Seidah and colleagues (Journal of Chromatography A, 1980) further purified and characterized this POMC-derived fragment and its precursor relationships. The distinct γ2-MSH subform arises when the prohormone convertase PC2 cleaves the γ3-MSH precursor; where dibasic Arg-Arg cleavage is incomplete, the C-terminal arginine is retained, producing the "Arg peptide" variant. Research on γ2-MSH expanded through the 2000s as the melanocortin receptor family's roles in obesity, energy balance, and sexual function became clear — driving demand for subtype-selective probes (Hruby and colleagues, Journal of Medicinal Chemistry, 2003; Cai and colleagues, Current Protein & Peptide Science, 2016).
What it does
γ2-MSH-Arg activates melanocortin receptors — cell-surface proteins distributed across the brain and peripheral tissues that regulate appetite, energy use, sodium handling, and reproductive function. The peptide preferentially activates MC3R over MC4R at human receptors, making it useful in experiments designed to distinguish which receptor is responsible for a given physiological effect. Because MC4R is the receptor most strongly linked to feeding behavior and weight regulation, and MC3R plays a more supporting role in metabolic homeostasis and circadian entrainment of energy cues, having a ligand that favors MC3R helps researchers isolate each receptor's contribution (Girardet and Butler, Biochimica et Biophysica Acta, 2013). γ2-MSH has also been studied for effects on sodium balance and blood pressure that appear to be mediated centrally rather than by direct renal action (Kathpalia and colleagues, Peptides, 2011).
Evidence
- Human: No human clinical trials. γ2-MSH-Arg is a research tool peptide; its value lies in receptor pharmacology studies rather than direct therapeutic application.
- Animal: Rodent studies using γ-MSH peptides have documented cardiovascular effects, natriuresis, and food intake modulation, though interpreting these results requires caution: Joseph and colleagues (Peptides, 2010) demonstrated that γ2-MSH is not selective for mouse MC3R over mouse MC5R (EC50 ~38 nM at mMC3R vs. ~42 nM at mMC5R), meaning some reported mouse physiological effects attributed to MC3R may also involve MC5R.
- In vitro: Receptor activation profiles have been characterized at all five melanocortin receptor subtypes. At mouse receptors, EC50 values of approximately 38 nM (mMC3R), 420 nM (mMC4R), and 42 nM (mMC5R) have been reported (Joseph and colleagues, Peptides, 2010). At human receptors, γ2-MSH shows roughly 44-fold selectivity for hMC3R over hMC4R and roughly 83-fold selectivity over hMC5R — a species difference that is relevant to translating rodent data to human biology.
Mechanism
γ2-MSH-Arg, like all melanocortin peptides, engages receptors through the conserved His-Phe-Arg-Trp pharmacophore embedded in its sequence. This tetrapeptide core makes contact with the orthosteric binding pocket shared across the melanocortin receptor family; once bound, the receptor couples to Gs protein and stimulates adenylate cyclase, raising intracellular cAMP. The surrounding residues determine receptor subtype selectivity: truncation and mutagenesis studies showed that the C-terminal Trp-Asp-Arg-Phe residues (positions 8–11 in γ2-MSH) are particularly important for nanomolar potency at MC3R, while the Arg-Trp dipeptide drives MC5R activity (Joseph and colleagues, Peptides, 2010). The N-terminal Tyr-Val-Met-Gly segment can be removed with only modest potency loss. Structure-activity studies by Balse-Srinivasan, Grieco, Cai, Trivedi, and Hruby (Journal of Medicinal Chemistry, 2003) demonstrated that introducing cyclic constraints (disulfide or lactam bridges) around the His-Phe-Arg-Trp core can shift selectivity away from MC3R and toward MC4R — a finding that informed the design of MC4R-selective drug candidates. γ2-MSH is processed from the larger γ3-MSH precursor in tissues that express prohormone convertase PC2, including the hypothalamus and intermediate lobe of the pituitary.
Known effects
- MC3R activation — Preclinical; preferential agonist for human MC3R at nanomolar concentrations
- MC4R activation — Preclinical; weak agonist (~420 nM EC50 at mouse MC4R); useful as negative comparator in MC4R selectivity assays
- Natriuresis / sodium balance — Preclinical; γ-MSH peptides increase urinary sodium excretion in rodent models via central MC3R-dependent pathways
- Blood pressure modulation — Preclinical; high dietary sodium increases circulating γ-MSH; γ-MSH deficiency leads to salt-sensitive hypertension in rodent models (Kathpalia and colleagues, Peptides, 2011)
- Energy homeostasis signaling — Mechanistic; the MC3R/MC4R system in which this peptide operates is the principal hypothalamic axis controlling food intake and energy expenditure (Girardet and Butler, Biochimica et Biophysica Acta, 2013)
Related peptides
The melanocortin receptor system includes several peptides that share the His-Phe-Arg-Trp pharmacophore and act at overlapping receptor profiles:
- α-MSH — the primary endogenous MC4R agonist and the most studied POMC-derived melanocortin; central to appetite suppression and pigmentation signaling
- Setmelanotide — FDA-approved cyclic MC4R agonist for genetic obesity caused by POMC or leptin receptor deficiency; structurally related but with far higher MC4R selectivity than γ2-MSH (Prindle and colleagues, Frontiers in Endocrinology, 2026)
- PT-141 / bremelanotide — MC3R/MC4R agonist FDA-approved for hypoactive sexual desire disorder; exploits the sexual function arm of MC4R signaling that γ2-MSH-Arg also engages at its receptor targets
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could this appetite-controlling peptide also relieve pain by acting on the same receptor type found on pain-sensing nerve cells?
The opioid crisis has made finding non-addictive painkillers a major medical priority. If this peptide can control pain through a completely different receptor, one that has nothing to do with opioids, it could contribute to a new class of non-addictive pain treatments that are also less prone to overdose and abuse.
If two specific parts of this peptide were chemically connected to form a ring, would it become more stable in the body and bind the appetite receptor more tightly?
Most peptides are broken down too quickly in the body to be useful drugs. The only approved drug of this type, setmelanotide, works precisely because it is made into a ring shape for stability. Applying the same strategy to this peptide, which already binds the receptor extremely well, could produce a new obesity drug that is both long-lasting and highly effective.
Is the single additional arginine at the end of this peptide responsible for making it bind the appetite-controlling receptor nearly perfectly?
Understanding which part of a peptide drives its receptor binding tells drug designers exactly what to preserve or build around. If a single arginine accounts for the near-perfect binding, synthetic drugs built around that arginine contact could be smaller, more stable, and cheaper to make than the full peptide.
Does the charged tail sequence of this peptide cause it to lock onto the appetite receptor while ignoring related receptors that could cause side effects?
The only approved drug of this type is setmelanotide, which works specifically on the appetite receptor. If gamma2-MSH-Arg naturally achieves the same selectivity through its tail sequence, it could be developed into a competing treatment for rare genetic obesity conditions, possibly with a better safety profile.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9622423648834229 | boltz-2 |
| ranking score | 0.8503326773643494 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.612 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep10722,
sequence = {YVMGHFRWDRFGR},
target = {mc4r},
author = {peptidemodel},
year = {2026},
status = {synthesized}
}